{"filing":{"accession_number":"0001193125-26-277556","cik":"0001801198","ticker":"LEGN","company_name":"Legend Biotech Corp","form":"6-K","filing_date":"2026-06-22","report_date":null,"primary_document":"d81029d6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1801198/000119312526277556/d81029d6k.htm"},"events":[{"id":12786,"run_id":11345,"accession_number":"0001193125-26-277556","anchor_item_number":"EX-99.1","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"Legend Biotech announced the pricing of a public offering of 7.7 million ADSs at $29.35 per share, generating approximately $226 million in gross proceeds. This is a material equity issuance that creates a direct financial obligation and dilutes existing shareholders. While technically an equity offering rather than debt, the taxonomy's `debt_issuance` category encompasses \"creation of a new direct financial obligation\" and is the closest fit for capital-raising activities that materially affect the registrant's financial structure and shareholder base.","company_name":"Legend Biotech Corp","ticker":"LEGN","filing_date":"2026-06-22","form":"6-K","submitted_at":null,"items":[{"id":9737,"accession_number":"0001193125-26-277556","item_number":"EX-99.1","item_title":"d81029dex991.htm","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Legend Biotech announced the pricing of a public offering of 7.7 million ADSs at $29.35 per share, generating approximately $226 million in gross proceeds. This is a material equity issuance that creates a direct financial obligation and dilutes existing shareholders. While technically an equity offering rather than debt, the taxonomy's `debt_issuance` category encompasses \"creation of a new direct financial obligation\" and is the closest fit for capital-raising activities that materially affect the registrant's financial structure and shareholder base.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-22T20:52:26.261630+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":9737,"accession_number":"0001193125-26-277556","item_number":"EX-99.1","item_title":"d81029dex991.htm","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Legend Biotech announced the pricing of a public offering of 7.7 million ADSs at $29.35 per share, generating approximately $226 million in gross proceeds. This is a material equity issuance that creates a direct financial obligation and dilutes existing shareholders. While technically an equity offering rather than debt, the taxonomy's `debt_issuance` category encompasses \"creation of a new direct financial obligation\" and is the closest fit for capital-raising activities that materially affect the registrant's financial structure and shareholder base.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-22T20:52:26.261630+00:00","company_name":"Legend Biotech Corp","ticker":"LEGN","filing_date":"2026-06-22"}]}